Key facts
- This page summarizes Chen Schor's Form 4 filing for Adicet Bio, Inc. (ACET).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 16 Feb 2022, 20:31.
Chen Schor - 14 Feb 2022 Form 4 Insider Report for Adicet Bio, Inc. (ACET)
- Reporting relationship
- President & CEO, Director
- Issuer ticker
- ACET
- Reported as of
- 14 Feb 2022
- Net transaction value
- -$303,780
- SEC form
- 4
- Accepted by SEC
- 16 Feb 2022, 20:31:54 UTC
- Prior SEC filing
- 01 Feb 2022
- Next SEC filing
- 20 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Nick Harvey, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Chen Schor filed Form 4 for Adicet Bio, Inc. (ACET) on 16 Feb 2022.
Change
- Previous filing in this sequence was filed on 01 Feb 2022.
- Current net transaction value: -$303,780.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACET
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +48,000
- Change %
- +39%
- Price
- $0.000000
- Shares after
- 170,712
- Date
- 14 Feb 2022
- Ownership
- Direct
- Footnotes
- F1
ACET
transaction
Common Stock
Tax liability
- Transaction value
- $303,780
- Shares
- -21,288
- Change %
- -12%
- Price
- $14.27
- Shares after
- 149,424
- Date
- 14 Feb 2022
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The Reporting Person was issued 240,000 Restricted Stock Units ("RSUs") on October 1, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 5, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 96,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. A total of 144,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Persons Restricted Stock Unit Agreement. On February 14, 2022, upon the occurrence of the second performance milestone, 48,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.